The business activities of Human Metabolome Technologies, a biotech venture originating at Keio University, as well as its growing orders for high-sensitivity analysis services and efforts to promote automation, were introduced.
Human Metabolome Technologies is primarily engaged in an advanced R&D support business providing metabolome and lipidome analyses, among other services, and is also pursuing a healthcare solutions business. It is positioned as a biotech venture originating at Keio University, and the company’s overview indicates that it is strengthening the provision of high-sensitivity comprehensive analysis services.
Against a backdrop of growing orders, the company is reportedly promoting the automation and efficiency improvements of its contract processes, with a policy of expanding the scope of its R&D support. The article contains no specific figures, and further updates are awaited.
The article was presented as a reprint of a FISCO stock comment and summarizes the business activities and current trends of Human Metabolome Technologies. The information was published on 30 September 2026, and the company’s positioning as a related stock is indicated.